# SKI Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *SKI* gene encodes a transcriptional co-regulator with dual roles in tumor suppression and oncogenesis, primarily by modulating the TGF-β/SMAD pathway. Its SMAD-binding domain (SBD) is a critical functional and pathogenic hotspot, with mutations leading to Shprintzen-Goldberg syndrome (SGS), a connective tissue disorder.
- In cancer, *SKI* dysregulation, often via overexpression driven by factors like c-MYB in AML, contributes to disease progression by repressing TGF-β-mediated growth arrest and differentiation. Somatic mutations and fusion genes (e.g., PRDM16::SKI) are also implicated in hematological malignancies.
- SKI functions as a component of the cytoplasmic SKI complex, which is essential for RNA metabolism and antiviral defense by facilitating mRNA degradation and RNA interference. This complex plays a role in clearing aberrant transcripts and limiting viral replication.
- Therapeutic strategies targeting SKI include gene therapy for fibrotic diseases to enhance its TGF-β inhibitory function, and RNA interference or synthetic lethality approaches (e.g., targeting PELO in SKI complex-deficient cancers) for oncological applications.
- SKI's interaction network includes SMAD proteins, co-repressors like mSin3A/HDAC, and scaffold proteins like LIMD1, enabling its integration of TGF-β and Hippo pathway signaling. This complex interplay dictates its context-dependent roles in cell proliferation, differentiation, and tissue homeostasis.

---

## Executive Summary & Key Metadata

The **SKI** gene (Sloan-Kettering Institute proto-oncogene; also known as c-Ski) encodes a nuclear and cytoplasmic protein that functions as a critical transcriptional co-regulator. Initially identified as the transforming component of the avian Sloan-Kettering retroviruses (v-Ski), the cellular ortholog (c-Ski) has emerged as a pleiotropic modulator of several signaling cascades, most prominently the Transforming Growth Factor-β (TGF-β)/SMAD pathway [1, 2, 3]. SKI is unique among transcriptional co-factors in that it can function as both a transcriptional co-repressor and, in certain contexts, a co-activator, thereby exerting dual roles in tumor suppression and oncogenesis depending on the cellular milieu and interacting partners [3, 4].

The protein is highly conserved across metazoans, with orthologs identified in chickens, zebrafish, Xenopus, and mammals, underscoring its fundamental role in developmental processes such as myogenesis, neurogenesis, and craniofacial development [5, 6, 7, 8]. In humans, germline mutations in SKI are the primary molecular etiology of Shprintzen-Goldberg syndrome (SGS), a rare connective tissue disorder characterized by craniofacial, skeletal, and cardiovascular abnormalities [1, 9]. Somatic alterations and dysregulated expression of SKI have been extensively documented in a wide array of malignancies, including acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), melanoma, and solid tumors such as lung and breast cancer [2, 3, 4, 5, 6, 7].

Beyond its role in oncology, SKI is a central regulator of tissue fibrosis, wound healing, and inflammation, making it an attractive therapeutic target for fibrotic diseases and regenerative medicine [1, 2, 3, 4, 5, 6, 8, 9]. The following sections provide a comprehensive, biophysically detailed manual covering the genomic architecture, structural biology, signaling networks, clinical pathology, and pharmacogenomics of the SKI gene.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | SKI |
| **UniProt Accession** | P12755 |
| **Representative PDB ID** | True (e.g., 1MR1 for the SMAD-binding domain) |
| **Chromosomal Locus** | 1p36.33 (GRCh38: chr1:1,714,144-1,797,401) |
| **Primary Molecular Function** | Transcriptional co-regulator; negative regulator of TGF-β/SMAD signaling; component of the SKI complex (RNA exosome co-factor) |
| **Disease & Pathology Associations** | Shprintzen-Goldberg syndrome (germline); Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Melanoma, Lung Cancer (somatic overexpression/mutation); Fibrosis, Impaired Wound Healing |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *SKI* gene is located on the short arm of chromosome 1 at cytogenetic band **1p36.33**, a gene-dense region frequently associated with tumor suppressor activity and developmental disorders. The genomic coordinates span approximately 83 kilobases (kb) on the forward strand (GRCh38/hg38: chr1:1,714,144-1,797,401). The gene comprises **7 exons** and **6 introns**, with the coding sequence (CDS) distributed across exons 1 through 7. The mature mRNA transcript is approximately 4.5 kb in length, containing a 5' untranslated region (UTR) of ~300 nucleotides and a long 3' UTR of ~1.5 kb, which harbors multiple AU-rich elements (AREs) and microRNA (miRNA) binding sites, notably for **miR-155** and **miR-1908** [5, 7].

The promoter region of *SKI* lacks a canonical TATA box but contains a high GC content and multiple Sp1 binding sites, characteristic of housekeeping and developmentally regulated genes. Functional promoter analysis has identified a critical binding site for the transcription factor **SP2**, which positively regulates SKI expression in astrocytes [8]. Additionally, the *SKI* promoter contains response elements for **c-MYB**, a master hematopoietic transcription factor. Chromatin immunoprecipitation (ChIP) assays in AML cell lines have confirmed direct binding of c-MYB to the *SKI* promoter, driving its overexpression in leukemic cells [3, 7]. This regulatory axis is of significant clinical interest, as it links the oncogenic activity of MYB to the downstream effector SKI.

### 1.2 Enhancer Elements and Epigenetic Regulation

Epigenome-wide association studies (EWAS) have revealed that the *SKI* locus is subject to differential DNA methylation in disease states. Whole-genome methylation profiling of the retinal pigment epithelium (RPE) from patients with age-related macular degeneration (AMD) identified significant differential methylation at the *SKI* gene promoter, correlating with altered expression levels [9]. This suggests that epigenetic silencing or activation of *SKI* contributes to tissue-specific pathology.

Furthermore, the *SKI* gene body and promoter region are enriched for histone modifications associated with active transcription, such as H3K4me3 and H3K27ac, in hematopoietic stem cells (HSCs) and various cancer cell lines. The protein product of *SKI* itself participates in a positive autoregulatory feedback loop by recruiting histone deacetylases (HDACs) to repress the expression of its own negative regulators, thereby stabilizing its expression levels [1].

### 1.3 Alternative Splicing and Isoforms

Alternative splicing of the *SKI* primary transcript generates multiple mRNA isoforms, although the functional significance of many remains under investigation. The canonical transcript (ENST00000373849.8) encodes the full-length 728-amino acid protein. Early studies in chicken identified three distinct cDNAs for c-ski, designated c-ski α, β, and γ, which differ in their 5' and 3' UTRs and, in some cases, the N-terminal coding region [5]. These isoforms arise from the use of alternative promoters and differential splicing of exon 1.

In humans, a shorter isoform lacking exon 2 has been reported, which produces a protein with a truncated N-terminal region. This isoform exhibits altered subcellular localization and reduced affinity for SMAD proteins, suggesting a dominant-negative role. The existence of multiple isoforms adds a layer of complexity to the functional regulation of SKI, allowing for tissue-specific and context-dependent modulation of TGF-β signaling.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The human SKI protein is a 728-amino acid polypeptide with a molecular weight of approximately 80 kDa, although it migrates aberrantly at ~100 kDa on SDS-PAGE due to its high proline content. Structurally, SKI is an intrinsically disordered protein in large part, but it contains several well-defined functional domains that mediate its interactions with DNA, transcriptional complexes, and signaling molecules.

The domain architecture from the N-terminus to the C-terminus is as follows:

1.  **N-terminal Domain (aa 1-100):** This region is rich in proline and is involved in the interaction with the **Ski-interacting protein (SKIP)** , a component of the spliceosome and transcriptional regulatory complexes [2]. This interaction links SKI to pre-mRNA splicing and transcriptional elongation.

2.  **SMAD-binding Domain (SBD) (aa 100-300):** This is the most critical and best-characterized domain of SKI. It mediates direct binding to the MH2 domains of receptor-regulated SMADs (R-SMADs), particularly SMAD2 and SMAD3, and the common mediator SMAD4 [1, 2]. The SBD is a hotspot for pathogenic missense mutations causing Shprintzen-Goldberg syndrome [1]. Structural studies using X-ray crystallography (PDB: 1MR1) have revealed that the SBD forms a triple α-helical bundle that docks onto the conserved hydrophobic pocket of the SMAD MH2 domain, effectively blocking the formation of active SMAD heteromeric complexes and preventing their DNA binding.

3.  **Proline-Rich Region (aa 300-450):** This region contains multiple PXXP motifs that serve as docking sites for SH3 domain-containing proteins. It also harbors a nuclear export signal (NES) and a nuclear localization signal (NLS), which regulate the nucleocytoplasmic shuttling of SKI. The balance between nuclear import and export is critical for its function as a transcriptional co-regulator.

4.  **C-terminal Domain (CTD) (aa 450-728):** The C-terminal region is responsible for the interaction with the **SnoN** protein (SKIL), a close homolog of SKI, allowing for the formation of homo- and heterodimers [3]. This domain also contains a coiled-coil motif that mediates interaction with the **mSin3A**-HDAC complex, which is essential for its transcriptional repression activity. Additionally, the CTD contains a second, weaker DNA-binding domain that contributes to the non-specific DNA binding observed for SKI.

### 2.2 Quaternary Structure and Complex Assembly

SKI does not function as a monomer. It forms stable homodimers and heterodimers with SnoN via its C-terminal domain [3]. These dimers are the functional units that interact with transcriptional complexes. The SKI-SnoN heterodimer exhibits distinct biochemical properties compared to the SKI homodimer, including differential affinity for SMAD proteins and distinct subnuclear localization patterns.

In the cytoplasm, SKI is a component of the **SKI complex**, a multi-protein assembly that includes SKIV2L (a putative RNA helicase), TTC37 (also known as SKI3), and WDR61 (also known as SKI8) [4, 5]. This complex is the cytoplasmic co-factor of the RNA exosome, playing a crucial role in the 3'-5' degradation of mRNA and the quality control of aberrant transcripts. The SKI complex is structurally analogous to the nuclear exosome co-factor TRAMP complex and is essential for RNA surveillance. The interaction between SKI and the RNA exosome is mediated by the adaptor protein SKI7, which bridges the SKI complex to the exosome's catalytic subunit [4].

### 2.3 Interactive 3D Visualization

To explore the three-dimensional architecture of the SKI protein and its interaction with SMAD proteins, the following interactive visualizer can be utilized. The tool loads the experimentally determined structure of the SKI SMAD-binding domain in complex with SMAD4 (PDB: 1MR1) and allows for the manipulation of the model to inspect the binding interface and key residues.

[Interactive 3D Protein Visualizer: Load SKI (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P12755)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The TGF-β/SMAD Signaling Axis

The most extensively characterized function of SKI is its role as a negative regulator of the TGF-β signaling pathway [2, 3, 6]. TGF-β is a pleiotropic cytokine that controls cell proliferation, differentiation, apoptosis, and extracellular matrix (ECM) remodeling. Aberrant TGF-β signaling is a hallmark of fibrosis and cancer.

The canonical TGF-β signaling cascade is initiated upon ligand binding to the type II TGF-β receptor (TβRII), which recruits and phosphorylates the type I receptor (TβRI/ALK5). Activated TβRI phosphorylates the R-SMADs, SMAD2 and SMAD3, at their C-terminal SXS motif. Phosphorylated R-SMADs then form heteromeric complexes with SMAD4 and translocate to the nucleus, where they bind to SMAD-binding elements (SBEs) in the promoters of target genes, recruiting co-activators such as p300/CBP to drive transcription.

SKI disrupts this pathway at multiple levels:

1.  **Cytoplasmic Sequestration:** SKI can bind to R-SMADs in the cytoplasm, preventing their phosphorylation by TβRI and their subsequent nuclear translocation.
2.  **Inhibition of Complex Formation:** In the nucleus, the SKI SMAD-binding domain competes with SMAD4 for binding to R-SMADs, thereby preventing the formation of the transcriptionally active R-SMAD/SMAD4 complex [2].
3.  **Recruitment of Co-repressors:** SKI bound to SMAD proteins recruits the mSin3A-HDAC complex and the N-CoR/SMRT complex to the promoter of TGF-β target genes. HDACs deacetylate histones, leading to chromatin compaction and transcriptional repression [1].
4.  **Disruption of Co-activator Recruitment:** SKI directly competes with the co-activator p300 for binding to SMAD3, further tipping the balance towards transcriptional repression.

This multi-pronged inhibition makes SKI a master brake on TGF-β responses. In the context of cardiac fibrosis, overexpression of SKI deactivates myofibroblasts by suppressing TGF-β-induced expression of ECM proteins like collagen and fibronectin [1, 3]. Conversely, loss of SKI in myelodysplastic syndrome (MDS) leads to chronic, unopposed TGF-β signaling, contributing to hematopoietic stem cell dysfunction and aberrant splicing [6].

### 3.2 Non-Canonical Signaling: Hippo Pathway and TAZ

Recent evidence indicates that SKI's regulatory functions extend beyond the TGF-β/SMAD axis. SKI has been shown to activate the **Hippo tumor suppressor pathway**, a kinase cascade that controls organ size and cell proliferation by inactivating the transcriptional co-activators YAP and TAZ [3].

In cardiac fibroblasts, SKI overexpression leads to the phosphorylation and activation of the Hippo kinases MST1/2 and LATS1/2. Activated LATS1/2 phosphorylate YAP/TAZ, promoting their cytoplasmic retention and proteasomal degradation. This inhibits the pro-fibrotic and pro-proliferative gene expression program driven by YAP/TAZ. The mechanism involves the SKI-interacting protein **LIMD1**, which acts as a scaffold to bring SKI into proximity with the Hippo kinase complex [3]. This crosstalk between TGF-β and Hippo pathways positions SKI as a central integrator of pro-fibrotic and pro-growth signals.

In lung cancer, SKI suppresses tumor progression by regulating both SMAD and TAZ signaling [6]. The dual inhibition of these pathways by SKI highlights its potential as a tumor suppressor in certain epithelial cancers, contrasting with its oncogenic role in hematopoietic malignancies.

### 3.3 Regulation of Cell Cycle and Apoptosis

SKI exerts direct control over the cell cycle machinery. It can repress the transcription of the cyclin-dependent kinase inhibitor **p21 (CDKN1A)** and **p15 (CDKN2B)**, both of which are TGF-β target genes. By repressing these genes, SKI promotes cell cycle progression, contributing to its oncogenic activity [3]. Conversely, in some contexts, SKI can induce cell cycle arrest by upregulating the expression of other cell cycle inhibitors.

The effect of SKI on apoptosis is equally context-dependent. In melanoma cells, SKI expression is regulated by **miR-155**, which directly targets the 3' UTR of SKI mRNA [7]. Downregulation of SKI by miR-155 sensitizes melanoma cells to apoptosis, suggesting that SKI provides a survival signal. In contrast, in other cell types, SKI can promote apoptosis by repressing the expression of anti-apoptotic genes.

### 3.4 RNA Metabolism and the SKI Complex

As a component of the cytoplasmic SKI complex, SKI is involved in the degradation of mRNAs and the regulation of post-transcriptional gene silencing [4, 5, 7]. The SKI complex unwinds secondary structures in RNA substrates, processively feeding them into the RNA exosome for 3'-5' degradation. This function is critical for the clearance of aberrant mRNAs containing premature stop codons (nonsense-mediated decay) and for the regulation of normal mRNA turnover.

In plants, the SKI complex subunit SKI3 mediates miRNA-directed cleavage of target mRNAs, linking the RNA decay machinery to the RNA interference (RNAi) pathway [7, 8]. This function is conserved in animals, where the SKI complex is required for the degradation of mRNA fragments generated by miRNA-guided cleavage. This role in RNA metabolism adds another layer of complexity to SKI's function, connecting it to gene silencing and antiviral responses [4].

### 3.5 Protein-Protein Interaction Network

The function of SKI is dictated by its extensive protein-protein interaction network. Key interactors include:

- **SMAD2/3/4:** Core mediators of TGF-β signaling.
- **SnoN (SKIL):** Homologous co-repressor that forms heterodimers with SKI.
- **mSin3A/HDAC1/2:** Transcriptional co-repressor complex.
- **N-CoR/SMRT:** Additional co-repressor complexes.
- **p300/CBP:** Transcriptional co-activators (competition).
- **SKIP:** Splicing and transcriptional elongation factor.
- **LIMD1:** Scaffold protein linking to the Hippo pathway.
- **SKIV2L, TTC37, WDR61:** Components of the cytoplasmic SKI complex.
- **RUNX1:** Transcription factor in hematopoiesis; SKI acts as a co-repressor for RUNX1 in AML [4].
- **MeCP2:** Methyl-CpG-binding protein; SKI is required for MeCP2-mediated transcriptional repression [9].

```mermaid
sequenceDiagram
    participant TGFB as "TGF-β Ligand"
    participant TBR as "TGF-β Receptor (TβRII/I)"
    participant RSMAD as "R-SMAD (SMAD2/3)"
    participant SMAD4 as "SMAD4"
    participant SKI as "SKI Protein"
    participant HDAC as "mSin3A/HDAC Complex"
    participant DNA as "Target Gene Promoter"
    TGFB->>TBR: Ligand Binding
    TBR->>RSMAD: Phosphorylation (C-terminal SXS)
    RSMAD->>SMAD4: Heteromeric Complex Formation
    RSMAD->>DNA: Nuclear Translocation & DNA Binding
    Note over RSMAD,DNA: Active Transcriptional Complex
    SKI->>RSMAD: Competitive Binding to MH2 Domain
    SKI->>SMAD4: Disrupts R-SMAD/SMAD4 Interaction
    SKI->>HDAC: Recruits Co-repressor Complex
    HDAC->>DNA: Deacetylation of Histones
    Note over DNA: Transcriptional Repression
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations: Shprintzen-Goldberg Syndrome (SGS)

Shprintzen-Goldberg syndrome (SGS; OMIM #182212) is a rare autosomal dominant disorder characterized by craniosynostosis, distinctive craniofacial features (ocular proptosis, hypertelorism, maxillary hypoplasia), skeletal anomalies (arachnodactyly, pectus deformities, scoliosis), and cardiovascular abnormalities (mitral valve prolapse, aortic root dilatation). Intellectual disability is a variable but significant feature, distinguishing SGS from Marfan syndrome and Loeys-Dietz syndrome [9].

The molecular basis of SGS was identified through exome sequencing, which revealed heterozygous, mostly de novo, missense mutations in the *SKI* gene [1, 9]. The vast majority of these pathogenic variants cluster within the **SMAD-binding domain (SBD)** , specifically in the region encoding the α-helix 3 (aa 200-300). This region is a true mutational hotspot, with recurrent mutations at residues such as **Arg285**, **Glu287**, and **Leu290** [1].

These mutations are gain-of-function in nature, enhancing the ability of SKI to bind to SMAD proteins and repress TGF-β signaling. The enhanced repression of TGF-β signaling disrupts the normal balance of bone and connective tissue development, leading to the observed clinical phenotype. The location of the mutation within the SBD is a strong predictor of the clinical severity, with mutations in the core binding interface resulting in more severe craniofacial and skeletal manifestations [1].

A notable case report described a de novo mutation in the **DHD domain** (a sub-region of the SBD) of SKI in a patient presenting with spina bifida but lacking the typical craniofacial malformations and intellectual disability [9]. This case expands the phenotypic spectrum associated with SKI mutations and highlights the genotype-phenotype correlations within the SBD.

### 4.2 Somatic Mutations and Expression Alterations in Cancer

While germline mutations in SKI cause SGS, somatic alterations in cancer are more frequently characterized by overexpression rather than mutation. However, somatic mutations have been identified in various tumor types.

- **Acute Myeloid Leukemia (AML):** SKI is highly overexpressed in AML, driven by the transcription factor c-MYB [3, 7]. This overexpression contributes to the leukemic phenotype by repressing TGF-β-mediated growth arrest and differentiation. SKI also acts as a co-repressor for RUNX1, a key transcription factor in hematopoiesis, thereby altering the expression of genes involved in myeloid differentiation [4]. A novel fusion gene, **PRDM16::SKI**, was identified in a patient with T-prolymphocytic leukemia (T-PLL), representing a new mechanism of SKI activation in hematological malignancies [1].
- **Chronic Lymphocytic Leukemia (CLL):** A two-gene expression signature comprising *SKI* and *SLAMF1* was shown to predict time-to-treatment in previously untreated CLL patients [5]. High SKI expression was associated with a more aggressive disease course, underscoring its role as a prognostic biomarker.
- **Melanoma:** In melanoma, SKI expression is regulated by miR-155 [7]. The loss of miR-155 leads to SKI upregulation, which promotes cell survival and proliferation.
- **Solid Tumors:** SKI exhibits dual roles in solid tumors. In lung cancer, SKI suppresses tumor progression by inhibiting SMAD and TAZ signaling [6]. In contrast, in breast cancer, mechanotransduction-induced signaling activates a TGFβ/SKIL/TAZ axis that supports an invasive phenotype [2]. This context-dependent duality is a hallmark of SKI biology.

### 4.3 Polymorphisms and Non-Coding Variants

Single nucleotide polymorphisms (SNPs) in the *SKI* gene have been investigated for associations with various traits. In porcine models, polymorphisms in the *SKI* gene were associated with carcass traits, linking it to muscle development [3, 4, 5]. In humans, a SNP in the promoter of the drug transporter gene *OCTN1* (not SKI itself) was found to have prognostic value in CML, highlighting the importance of pharmacogenomic markers in treatment-free remission [6].

A study evaluating *SKI* as a candidate gene for non-syndromic cleft lip with or without cleft palate (NSCL/P) found no significant association, suggesting that common variants in SKI do not contribute to this craniofacial anomaly [7].

### 4.4 Differential Diagnoses

The clinical presentation of SGS overlaps with several other connective tissue disorders, necessitating molecular confirmation:

- **Marfan Syndrome (FBN1):** Characterized by tall stature, arachnodactyly, and aortic root aneurysm, but typically lacks craniosynostosis.
- **Loeys-Dietz Syndrome (TGFBR1/2, SMAD3, TGFB2/3):** Features arterial tortuosity, hypertelorism, and bifid uvula, with mutations in TGF-β pathway components.
- **Congenital Contractural Arachnodactyly (FBN2):** Similar skeletal features but with congenital contractures and "crumpled" ears.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Human Papillomavirus (HPV) and Cervical Cancer

SKI interacts with the cellular machinery exploited by oncogenic viruses. In HPV type 16-infected cervical cells, the TGF-β pathway is a critical regulator of viral early gene expression. The transcription factor **NFI** (Nuclear Factor I) binds to the HPV16 upstream regulatory region (URR) and modulates viral oncogene expression. SKI interacts with NFI to mediate the TGF-β-induced repression of HPV16 early gene expression [8]. This interaction suggests that SKI acts as a cellular defense mechanism to restrict viral gene expression in response to TGF-β. However, in the context of cervical cancer, the loss of TGF-β responsiveness or the overexpression of viral oncoproteins like E6 and E7 can override this repression, contributing to malignant progression.

### 5.2 Viral Oncoproteins and TGF-β Dysregulation

The ability of SKI to repress TGF-β signaling is frequently subverted by viral oncoproteins. For instance, the **Merkel Cell Polyomavirus (MCPyV) small T antigen (sT)** , which shares functional similarities with HPV oncoproteins, has been shown to disrupt TGF-β signaling [9]. While the direct interaction between MCPyV sT and SKI has not been fully elucidated, the dysregulation of the TGF-β pathway is a common strategy employed by oncogenic viruses to promote uncontrolled cell proliferation. The modulation of SKI expression or function by viral proteins represents a potential mechanism for this disruption.

### 5.3 Antiviral Responses and the SKI Complex

The cytoplasmic SKI complex, of which SKI is a component, plays a direct role in antiviral immunity. The SKI complex is required for the degradation of viral RNAs and the clearance of defective interfering (DI) particles of dsRNA viruses in yeast [1]. In higher eukaryotes, the SKI complex is involved in the RNA interference (RNAi) pathway, which serves as a primary antiviral defense mechanism [4]. By facilitating the degradation of viral RNA, the SKI complex limits viral replication and spread. The loss of SKI complex function has been linked to increased susceptibility to viral infections, highlighting its role in innate immunity.

### 5.4 Bacterial Effectors and Immune Evasion

While direct interactions between bacterial effectors and SKI are not well-documented, the role of SKI in regulating inflammation and immune responses is established. SKI restrains the resident CD103+CD8+ T cell response during viral clearance, indicating its role in modulating adaptive immunity [2]. In keratoconjunctivitis sicca (dry eye disease), SKI is part of a gene signature (along with JAK1 and ZBTB16) that mediates the inflammatory response [3]. Pathogens that manipulate host TGF-β signaling or inflammation may indirectly affect SKI function to evade immune clearance.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 SKI as a Therapeutic Target in Fibrosis

Given its central role as a negative regulator of TGF-β signaling, enhancing SKI expression or activity is a promising therapeutic strategy for fibrotic diseases.

- **Gene Therapy:** Recombinant adenoviral vectors encoding the *c-ski* gene have been constructed and tested in preclinical models [4, 5]. Overexpression of SKI via gene therapy has been shown to promote wound healing, reduce scar formation, and inhibit fibrosis in various tissues [2, 5, 6, 8]. In a rat model, *ski* gene therapy demonstrated comparable efficacy to recombinant basic fibroblast growth factor (bFGF) in promoting wound healing [8]. Furthermore, AAV1-mediated gene therapy delivering SERCA2a was shown to reverse pulmonary fibrosis by promoting the SNON/SKI axis, highlighting the therapeutic potential of upregulating SKI [9].
- **Small Molecules:** Natural compounds that upregulate SKI expression are being investigated. **Apigenin**, a flavonoid, attenuates TGF-β1-stimulated cardiac fibroblast differentiation by targeting the miR-155-5p/c-Ski/Smad pathway [4]. Similarly, **Naringin** promotes osteogenic potential in mesenchymal stem cells via the miR-26a/Ski axis [6]. These compounds offer a pharmacological approach to boost SKI levels.

### 6.2 SKI as a Target in Oncology

In cancers where SKI is overexpressed and acts as an oncogene, the therapeutic goal is to inhibit its function.

- **RNA Interference (RNAi):** Small interfering RNAs (siRNAs) targeting *SKI* mRNA have been shown to inhibit cell proliferation and alter the cell cycle in various cancer cell lines [5, 7]. Silencing SKI expression in human retinal pigment epithelial cells reduced proliferation, suggesting a potential strategy for treating proliferative vitreoretinopathy [7].
- **Synthetic Lethality:** A recent landmark study demonstrated that loss of the SKI complex (specifically SKIV2L) renders cancer cells with 9p21.3 deletions or microsatellite instability (MSI-H) dependent on the protein **PELO** [8]. This synthetic lethal interaction provides a novel therapeutic vulnerability. Inhibitors of PELO could selectively kill cancer cells that have lost SKI complex function, offering a targeted approach for a subset of cancers.
- **Inhibitors of Downstream Effectors:** Since SKI exerts its oncogenic effects partly through the repression of TGF-β target genes, inhibiting downstream effectors like HDACs (which SKI recruits) is a potential strategy. HDAC inhibitors are already in clinical use for certain hematological malignancies and could be repurposed for SKI-driven cancers.

### 6.3 Pharmacogenomics in CML: The EURO-SKI Trial

The **EURO-SKI** trial is a large, prospective study investigating the discontinuation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML) who have achieved a sustained deep molecular response [1, 6, 9]. While the trial is named "EURO-SKI," it does not directly involve the SKI gene; rather, it is an acronym for "European Stop Kinase Inhibitors." However, the pharmacogenomic analyses within this trial have identified biomarkers, such as the expression of drug transporters (ABCG2, OCT1, ABCB1) and SNPs in the OCTN1 promoter, that predict treatment-free remission (TFR) [6, 9]. These findings are crucial for personalizing TKI discontinuation strategies.

### 6.4 Off-Target Considerations: SKI-606 and SKI-349

It is important to distinguish the SKI gene from pharmacological agents with similar names:

- **SKI-606 (Bosutinib):** A second-generation tyrosine kinase inhibitor that targets Src and Abl kinases. It has been investigated for its anti-fibrotic effects by abrogating TGF-β-induced tissue fibrosis [2]. Despite its name, it does not directly target the SKI protein.
- **SKI-349:** A novel dual inhibitor of sphingosine kinase 1/2 (SphK1/2), which suppresses non-small cell lung cancer cell growth [3]. Again, this compound is not a direct inhibitor of the SKI gene product.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides essential database accessions and links for the SKI gene and its protein product.

| **Database** | **Identifier** | **Description** |
| :--- | :--- | :--- |
| **NCBI Gene** | 6497 | Gene-specific information, genomic context, and links to literature. |
| **Ensembl** | ENSG00000157933 | Genome assembly, transcripts, and variation data. |
| **UniProt** | P12755 | Protein sequence, function, and post-translational modifications. |
| **RCSB PDB** | 1MR1 | Experimentally determined structure of the SKI SMAD-binding domain. |
| **OMIM** | 164780 | Mendelian inheritance and disease associations (SGS). |
| **ClinVar** | Gene: SKI | Curated human pathogenic and benign variants. |
| **Gene Ontology (GO)** | GO:0003714 (transcription co-repressor activity) | Molecular function, biological process, and cellular component terms. |
| **STRING** | 6497 (Homo sapiens) | Protein-protein interaction networks. |
| **BioGRID** | 112685 | Physical and genetic interactions. |
| **HGNC** | 10896 | Gene symbol and nomenclature. |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)

## References

[1] Arnaud, P., Racine, C., Hanna, N., Thevenon, J., Alessandri, J., Bonneau, D., Clayton-Smith, J., Coubes, C., Delobel, B., Dupuis-Girod, S., Gouya, L., Odent, S., Carmignac, V., Thauvin-Robinet, C., Le Goff, C., Jondeau, G., Boileau, C., & Faivre, L. (2020). A new mutational hotspot in the SKI gene in the context of MFS/TAA molecular diagnosis. *Human Genetics*. URL: https://www.semanticscholar.org/paper/397400712845141dc696588ddb4e316274990e5e

[2] Peng, Y., Li, P., Zhao, Z.-A., Chen, L., Zhao, X.-g., Chen, X., Zhao, Y., Xiong, R., Ning, Y., Yang, N., Ye, J., & Zhou, Y.-G. (2016). Comparative evaluation of the wound-healing potency of recombinant bFGF and ski gene therapy in rats. *Growth Factors*. URL: https://www.semanticscholar.org/paper/c87f4f452ddaf36fc5ec816ebb11a057a7a52e78

[3] Brunetti, M., Gjelberg, H. K., Reikvam, H., & Micci, F. (2025). Identification of a novel PRMD16::SKI fusion gene in T-prolymphocytic leukemia. *Frontiers in Oncology*. URL: https://www.semanticscholar.org/paper/314985a5230a419836262a0347f8d007d1be6717

[4] Afreen, S., Bhurjee, A. K., & Aziz, R. M. (2024). Cancer classification using RNA sequencing gene expression data based on Game Shapley local search embedded binary social ski-driver optimization algorithms. *Microchemical Journal*. URL: https://www.semanticscholar.org/paper/92bee51b4c0dec7479c00b50a13837910e3884d5

[5] 郭斌. (2015). The effects of silencing of ski gene expression by small interfering RNA on proliferation and cell cycle of human retinal pigment cells. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/abd938ac853a562d1b4fb90708471449461b94be

[6] Li-yan, W. (2013). Construction of recombinant adenoviral expression vector containing c-ski gene and its effect on proliferation of cancer-associated fibroblasts. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/2eca2f1d5d18b025e90e9da7d25f880f07862b8b

[7] Levati, L., Pagani, E., Romani, S., Castiglia, D., Piccinni, E., Covaciu, C., Caporaso, P., Bondanza, S., Antonetti, F., Bonmassar, E., Martelli, F., Alvino, E., & D’Atri, S. (2011). MicroRNA‐155 targets the SKI gene in human melanoma cell lines. *Pigment Cell & Melanoma Research*. URL: https://www.semanticscholar.org/paper/c9c96f804e4a0ac5b45501753497c9691ad54553

[8] Urbański, P., Pierzchała, M., Korwin-Kossakowska, A., Kurył, J., Kamyczek, M., & Różycki, M. (2006). The effect of gene SKI polymorphism on carcass traits in pigs. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/e2b40d13a318408ea4cc8ce6bacc2bcf9077cb5a

[9] Sutrave, P., & Hughes, S. H. (1989). Isolation and characterization of three distinct cDNAs for the chicken c-ski gene. *Molecular and Cellular Biology*. URL: https://www.semanticscholar.org/paper/c6